Aripiprazol
| Evidensnivå: L5 | Förutsagda indikationer: 0 st |
Innehållsförteckning
Aripiprazole: Evaluation Pending — No Predicted Indication Available
One-Sentence Summary
Aripiprazole (INN: ARIPIPRAZOL) is a well-known atypical antipsychotic widely used globally for schizophrenia, bipolar disorder, and as adjunctive treatment for major depressive disorder. However, the current Evidence Pack contains no TxGNN predicted indications, no original indication records, and no safety data, making a full drug repurposing evaluation impossible at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (known globally: schizophrenia, bipolar disorder, MDD adjunct) |
| Predicted New Indication | None — TxGNN prediction not yet run or returned no results |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (no evidence available) |
| Sweden Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, no TxGNN prediction is available for aripiprazole, so a mechanistic plausibility assessment cannot be performed.
For context, aripiprazole is a third-generation atypical antipsychotic that functions as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at serotonin 5-HT2A receptors. This unique "dopamine system stabilizer" profile distinguishes it from other antipsychotics. The mechanism of action field in this evidence pack is listed as a data gap, but aripiprazole's pharmacology is well-characterized in the published literature (DrugBank ID: DB01238).
Once TxGNN predictions become available, the partial agonist mechanism could support plausible repurposing directions in neuropsychiatric, neurodegenerative, or impulse-control spectrum disorders. A re-evaluation should be conducted after the prediction pipeline is complete.
Clinical Trial Evidence
Currently no predicted indication has been generated, therefore clinical trial evidence has not been collected for a specific repurposing direction.
Note: Globally, aripiprazole has been studied in over 1,000 clinical trials across multiple indications. Once a specific predicted indication is available, targeted trial evidence can be compiled.
Literature Evidence
Currently no predicted indication has been generated, therefore literature evidence has not been collected for a specific repurposing direction.
Sweden Market Information
Aripiprazole is not currently marketed in Sweden according to the evidence pack (0 authorizations found).
Note: This result may reflect a query using the variant spelling "ARIPIPRAZOL" rather than "ARIPIPRAZOLE". A re-query with the corrected INN spelling is recommended. Globally, aripiprazole is marketed under brand names including Abilify® (Otsuka/Bristol-Myers Squibb) and numerous generic formulations.
Safety Considerations
Please refer to the package insert for safety information.
Key safety data (warnings, contraindications, drug-drug interactions) were not available in this evidence pack. For aripiprazole, clinicians should be aware of the following well-established safety concerns from global labelling:
- Black Box Warning (US FDA): Increased mortality in elderly patients with dementia-related psychosis; suicidality risk in children/adolescents/young adults
- Common adverse effects: Akathisia, insomnia, nausea, restlessness, weight gain
- Metabolic monitoring: Blood glucose, lipid profile, body weight
A formal safety assessment requires the package insert data gap (DG001) to be resolved.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence pack is critically incomplete — there is no TxGNN predicted indication, no registered authorizations in the queried market, and all safety data fields are empty. Without a target indication, no repurposing evaluation can proceed.
To proceed, the following is needed:
- Re-run TxGNN prediction for aripiprazole (verify input uses correct INN: "aripiprazole" / DrugBank ID: DB01238)
- Correct the INN spelling in queries: "ARIPIPRAZOL" → "ARIPIPRAZOLE" (the trailing 'e' may be causing lookup failures)
- Resolve DG001: Obtain package insert warnings and contraindications from the relevant regulatory authority
- Resolve DG002: Retrieve mechanism of action data from DrugBank (DB01238) to enable mechanistic plausibility assessment
- Re-query market authorization databases with the corrected drug name to confirm market status
- Re-generate the Evidence Pack once the above gaps are filled, then re-evaluate
This report was generated on 2026-04-03. Results are for research reference only and do not constitute medical advice. Drug repurposing candidates require clinical validation before application.
Ansvarsfriskrivning
Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning. Klinisk validering krävs före klinisk tillämpning.